J Rheum Dis.  2013 Jun;20(3):198-201. 10.4078/jrd.2013.20.3.198.

A Case of Skin Sclerosis Associated with Docetaxel Chemotherapy for Non-Small Cell Lung Cancer

• Nam JH
• Moon JJ
• Lee JH
• Park SW
• Jang AS
• Kim DJ
• Jeon CH
• Koh ES

• KMID: 2222762
• DOI: http://doi.org/10.4078/jrd.2013.20.3.198

Abstract

A 64-year-old woman was diagnosed with non-small cell lung cancer. Her disease was stage 4 (T2N2M1) with squamous cell carcinoma. She had been treated with docetaxel and carboplatin. After a completion of 11 cycle of chemotherapy, edema appeared on both feet and had spread rapidly up to the pretibial area without response to diuretics. Sclerotic changes and pigmentation followed but both knees and other parts of the body were spared. There was no evidence of vascular occlusions. On serologic tests, antinuclear, anti-centromere, and anti-topoisomerase I antibodies were all negative. A skin biopsy revealed diffuse infiltration of lymphocytes and discretely thickened collagen bundles in the superficial dermis. After discontinuing docetaxel chemotherapy, she was treated with prednisolone and D-penicillamine and sclerotic changes on the lower legs were improved.

Keyword

Docetaxel; Scleroderma; Lung cancer; Adverse effect

MeSH Terms

Antibodies
Biopsy
Carboplatin
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Collagen
Dermis
Diuretics
Edema
Female
Foot
Glycogen Storage Disease Type VI
Humans
Knee
Leg
Lung Neoplasms
Lymphocytes
Penicillamine
Pigmentation
Prednisolone
Sclerosis
Serologic Tests
Skin
Taxoids
Antibodies
Carboplatin
Collagen
Diuretics
Penicillamine
Prednisolone
Taxoids

Figure

• 

  Figure 1. Low magnification findings show mild acnthosis and superficial perivascular Inflammatory cell infiltrate (H&E, ×40).

• 

  Figure 2. Reticular dermis show thickened collagen bundles (H&E, ×200).

• 

  Figure 3. Subcutaneous collagen is pale and eosinophilic with a few lymphocytic infiltrate & endothelial swelling (H&E, ×200).

Reference

References

1. Trudeau ME. Docetaxel: a review of its pharmacology and clinical activity. Can J Oncol. 1996; 6:443–57.

2. Verweij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol. 1994; 5:495–505.

3. Arwert L. Docetaxel-induced skin toxicity. Neth J Med. 2009; 67:33–4.

4. De Angelis R, Bugatti L, Cerioni A, Del Medico P, Filosa G. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol. 2003; 22:49–52.

5. Farrant PB, Mortimer PS, Gore M. Scleroderma and the taxanes. Is there really a link? Clin Exp Dermatol. 2004; 29:360–2.

6. Sakkas LI, Moore DF, Akritidis NC. Cancer in families with systemic sclerosis. Am J Med Sci. 1995; 310:223–5.

7. Kim HJ, Seo YI, Kwon YS, Kim YM, Park EJ, Kim HA. A case of paclitaxel induced scleroderma in a patient with ovarian cancer. J Rheum Dis. 2011; 18:110–3.

8. Yoon JH, Choi K, Seo HI, Lee YS, Oh SJ, Lee SS. A case of paclitaxel induced scleroderma. Korean J Med. 2006; 70:S373–6.

9. Karim M, Vaux E, Davies DR, Mason PD. Renal failure due to scleroderma with thrombotic microangiopathy developing in a woman treated with carboplatin for ovarian cancer. Clin Nephrol. 2002; 58:384–8.

10. Wigley FM, Sule SD. Novel therapy in the treatment of scleroderma. Expert Opin Investig Drugs. 2001; 10:31–48.